Anton Oseledchyk

ORCID: 0009-0008-8953-5103
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Ovarian cancer diagnosis and treatment
  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • Spectroscopy Techniques in Biomedical and Chemical Research
  • Intraperitoneal and Appendiceal Malignancies
  • CAR-T cell therapy research
  • Virus-based gene therapy research
  • Endometrial and Cervical Cancer Treatments
  • Gold and Silver Nanoparticles Synthesis and Applications
  • Biosensors and Analytical Detection
  • Immunotherapy and Immune Responses
  • Cancer Research and Treatments
  • Fetal and Pediatric Neurological Disorders
  • Nanoplatforms for cancer theranostics
  • Nanoparticle-Based Drug Delivery
  • Animal Virus Infections Studies
  • Advanced biosensing and bioanalysis techniques
  • Cancer Immunotherapy and Biomarkers
  • Male Breast Health Studies
  • Cancer Treatment and Pharmacology
  • Endometriosis Research and Treatment
  • HER2/EGFR in Cancer Research
  • Multiple and Secondary Primary Cancers
  • BRCA gene mutations in cancer
  • Cancer-related Molecular Pathways

University of Basel
2025

Memorial Sloan Kettering Cancer Center
2016-2023

University Hospital of Basel
2023

University of Bonn
2014-2022

Helios Hospital Berlin-Buch
2021

Swim Across America
2018

University Hospital Bonn
2012-2015

Complete surgical resection is the ideal first-line treatment for most liver malignancies. This goal would be facilitated by an intraoperative imaging method that enables more precise visualization of tumor margins and detection otherwise invisible microscopic lesions. To this end, we synthesized silica-encapsulated surface-enhanced Raman scattering (SERS) nanoparticles (NPs) act as a molecular agent We hypothesized that, after intravenous administration, SERS NPs avidly home to healthy...

10.1021/acsnano.5b07200 article EN ACS Nano 2016-04-14

Ovarian cancer has a unique pattern of metastatic spread, in that it initially spreads locally within the peritoneal cavity. This is contrast to most other types, which metastasize early on via bloodstream distant sites. behavior opens up an opportunity for local application both therapeutic and imaging agents. Upon initial diagnosis, 75% patients already present with diffuse spread involving abdominal organs. Complete resection all tumor implants been shown be major factor improved...

10.1021/acsnano.6b06796 article EN ACS Nano 2016-12-19

Intralesional therapy with oncolytic viruses (OVs) leads to the activation of local and systemic immune pathways, which may present targets for further combinatorial therapies. Here, we used human tumor histocultures as well syngeneic models treated Newcastle disease virus (NDV) identify a range upregulated OV treatment. Despite infiltration effector T lymphocytes in response NDV, there was ongoing inhibition through programmed death ligand 1 (PD-L1), acting mechanism early late adaptive...

10.1172/jci98047 article EN Journal of Clinical Investigation 2018-03-04

Anti-viral immunity presents a major hurdle for systemically administered oncolytic viruses (OV). Intratumoral OV therapy has potential to overcome this problem through activation of anti-tumor immune response, with local and abscopal effects. However, the effects anti-viral in such setting are still not well defined. Using Newcastle Disease Virus (NDV) as model, we explore pre-existing on therapeutic efficacy syngeneic mouse tumor models. Unexpectedly, find that while NDV limits its...

10.1016/j.ymthe.2018.01.019 article EN cc-by-nc-nd Molecular Therapy 2018-02-01

Abstract Recently, surface-enhanced Raman scattering nanoprobes have shown tremendous potential in oncological imaging owing to the high sensitivity and specificity of their fingerprint-like spectra. As current scanners rely on a slow, point-by-point spectrum acquisition, there is an unmet need for faster cover clinically relevant area real-time. Herein, we report rational design optimization fluorescence-Raman bimodal nanoparticles (FRNPs) that synergistically combine spectroscopy with...

10.1038/s41467-019-09173-2 article EN cc-by Nature Communications 2019-04-26

Recently, surface‐enhanced Raman scattering (SERS) nanoprobes (NPs) have shown promise in the field of cancer imaging due to their unparalleled signal specificity and high sensitivity. This study reports development a DNA aptamer targeted SERS NP. aptamers are being investigated as viable alternative more traditional antibody targeting low immunogenicity cost production. A strategy is developed functionalize NPs with aptamers, which target Mucin1 (MUC1) human breast (BC). Thorough vitro...

10.1002/adfm.201606632 article EN Advanced Functional Materials 2017-07-06

Here we demonstrate a novel application of 'surface enhanced resonance Raman scattering nanoparticles' (SERRS NPs) for imaging breast cancer lung metastases with much higher precision than currently feasible. A metastasis mouse model was established by intravenous injection LM2 cells. These mice were intravenously administered SERRS NPs conjugated ALT-836, an anti-tissue factor (TF) monoclonal antibody, and subjected to visualize the expression TF both in vivo ex vivo. indicated marked...

10.1039/c6nr08217c article EN Nanoscale 2016-11-22

Abstract CAR T-cell therapy has improved outcomes for patients with chemotherapy-resistant B-cell malignancies. However, treatment of solid cancers been more difficult, in part because the heterogeneous expression tumor-specific cell surface antigens. Here, we describe generation a fully human targeting altered glycosylation secretory epithelial cancers. The target antigen – truncated, sialylated O-glycan sialyl-Thomsen-Nouveau (STn) was studied highly STn-specific antibody across various...

10.1158/2326-6066.cir-24-1050 article EN Cancer Immunology Research 2025-04-16

Intratumoral therapy with oncolytic viruses is increasingly being explored as a strategy to potentiate an immune response against cancer, but it remains unknown whether such should be restricted cancers sensitive virus-mediated lysis. Using Newcastle Disease Virus (NDV) model, we explore immunogenic potential of virus in bladder where existing immunotherapy PD-1 and PD-L1-targeting antibodies date has shown suboptimal rates. Infection human mouse cancer cells NDV resulted cell death,...

10.18632/oncotarget.25614 article EN Oncotarget 2018-06-18

Abstract Adjuvant chemotherapy is recommended for patients with resected high‐risk adult granulosa cell tumors ( GCT ), although strong data to support this are lacking. The objective of study was assess the outcomes patients, specific focus on that received adjuvant curative intent (stage I‐ III reported in a large national cancer registry. Data from Surveillance, Epidemiology, and End Results SEER ) database between 2000 2013 were used analysis. Patient disease characteristics extracted...

10.1002/cam4.1447 article EN cc-by Cancer Medicine 2018-04-17

Visualizing the presence and distribution of multiple specific molecular markers within a tumor can reveal composition its microenvironment, inform diagnosis, stratify patients, guide treatment. Raman imaging with molecularly-targeted surface enhanced scattering (SERS) nanoprobes could help investigate emerging cancer treatments preclinically or enable personalized treatment assessment. Here, we report comprehensive strategy for multiplexed using SERS machine learning (ML) to monitor early...

10.1039/d2nh00331g article EN cc-by-nc Nanoscale Horizons 2022-01-01

The aim of the study was to report prevalence and associated findings fetal ventriculomegaly between 11 + 0 13 6 gestational weeks evaluate a sonographic approach classify first trimester in standard axial plane used for biparietal diameter (BPD) measurement.The ratio choroid plexus lateral ventricle (PDVDR), length (PLVLR) area (PAVAR) were calculated from stored 2D images head 100 normal fetuses 17 with ventriculomegaly.The PDVDR, PLVLR PAVAR below 5(th) percentile 82.4%, 94.1% cases...

10.1186/s12884-016-0797-z article EN cc-by BMC Pregnancy and Childbirth 2016-01-11

Ovarian cancer represents the deadliest gynecologic malignancy. Most patients present at an advanced stage (FIGO III or IV), when local metastatic spread has already occurred. However, ovarian a unique pattern of spread, in that tumor implants are initially contained within peritoneal cavity. This feature could enable, principle, complete resection with curative intent. Many these lesions microscopic, making them hard to identify and treat. Neutralizing such micrometastases is believed be...

10.3791/58389 article EN Journal of Visualized Experiments 2019-03-25

Extensive surgical efforts to achieve an optimal debulking (no residual tumor) in primary surgery of ovarian cancer are today's criterion standard gyneco-oncologic surgery. However, it is controversial whether extensive surgery, including resections metastases the upper abdomen and bowel resections, justifiable patients with not completely operable lesions.All who had undergone for years 2002 2013 at our institution were viewed (n = 472). We retrospectively identified 278 operations cancer....

10.1097/igc.0000000000000707 article EN cc-by-nc-nd International Journal of Gynecological Cancer 2016-04-21

Abstract Purpose Real‐world data about pegylated liposomal doxorubicin (PLD) in patients with metastatic breast cancer (MBC) are limited. We have aimed to highlight the role of PLD daily practice focusing on older and comorbidities MBC. Methods analyzed electronic records all advanced/metastatic treated single‐agent at University Hospital Basel between 2003 2021. Primary endpoint was time next chemotherapy or death (TTNC). Secondary endpoints were overall survival (OS), progression‐free...

10.1002/cam4.6041 article EN cc-by Cancer Medicine 2023-05-06

There is controversy as to whether performing a total or subtotal colectomy justified in patients with advanced ovarian cancer, given its potential for morbidity and negative effect on long-term quality of life. The aim this study was assess the perioperative complications, mortality outcomes who underwent part surgical procedure primary recurrent epithelial cancer.All had undergone surgery including cancer between 2005 2013 at our institution were retrospectively identified.In time period,...

10.1159/000366249 article EN Oncology Research and Treatment 2014-01-01

In early luminal breast cancer, the Oncotype DX® Recurrence Score (RS) prognostic and predictive value with regards to chemotherapy (CHT) application benefit has been broadly validated. older patients its not deeply addressed. This study aimed evaluate benefits of RS testing look at differences in treatment allocation for these when compared younger ones.We included data from consecutive HER2-negative treated between 2010 2022 University Hospital Basel Cantonal Baselland, Switzerland. The...

10.1016/j.tranon.2023.101724 article EN cc-by-nc-nd Translational Oncology 2023-07-20

Ovarian cancer represents the deadliest gynecologic malignancy. Most patients present at an advanced stage (FIGO III or IV), when local metastatic spread has already occurred. However, ovarian a unique pattern of spread, in that tumor implants are initially contained within peritoneal cavity. This feature could enable, principle, complete resection with curative intent. Many these lesions microscopic, making them hard to identify and treat. Neutralizing such micrometastases is believed be...

10.3791/58389-v article EN Journal of Visualized Experiments 2019-03-25

<h3>Objective</h3> Ovarian suppression is recommended to complement endocrine therapy in premenopausal women with breast cancer and high-risk features. It can be achieved by either medical ovarian or therapeutic bilateral salpingo-oophorectomy. Our objective was evaluate characteristics of patients stage I–III hormone receptor positive primary who underwent salpingo-oophorectomy at our institution. <h3>Materials methods</h3> Premenopausal diagnosed between January 2010 December 2014 were...

10.1136/ijgc-2020-001966 article EN cc-by-nc-nd International Journal of Gynecological Cancer 2020-12-03

In patients with hormone receptor positive, human epidermal 2 negative (HR+/HER2−) breast cancer (BC), the TAILORx study showed benefit of adding chemotherapy (CHT) to endocrine therapy (ET) in a subgroup under 50 years an intermediate Oncotype DX recurrence score (RS 11–25). The aim present was determine if findings, including changes RS categories, impacted CHT use (11–25) group daily practice, as well identify main factors for decisions. We conducted retrospective on 326 BC (59%...

10.3390/diagnostics14010097 article EN cc-by Diagnostics 2023-12-31
Coming Soon ...